BioSpace News Archive

ZyVersa announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will provide a corporate update as an invited speaker at the BIO CEO & Investor Conference to be held in New York February 26 – 27, 2024.

Daxor Corporation announces the expansion of blood volume analysis through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service.

Vaccinex, Inc. announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company’s Board of Directors and the Company’s Chief Executive Officer.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-Infectives, today announced it signed a Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a leading Indonesian biomedical organization, to accelerate the clinical development of Recce’s anti-infective portfolio across Indonesia.

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Aethlon Medical, Inc. today announced that it will issue financial results for its fiscal third quarter ended December 31, 2023 , at 4:15 p.m. ET on Wednesday, February 14, 2024 .

Evaxion Biotech A/S announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550.

CervoMed Inc., a clinical-stage company developing treatments for degenerative diseases of the brain, announced the appointment of Joshua Boger, Ph.D., to its Board of Directors and as Chair of the Board.

Trinity Biotech Plc. has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.

T2 Biosystems, Inc. announced that the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation have selected T2 Biosystems as a Phase 2 winner in the LymeX Diagnostics Prize, a prize competition to accelerate the development of Lyme disease diagnostics.